Crystalline norpsilocin compounds
The disclosure relates to norpsilocin compounds, compositions containing those crystalline compounds, and methods of treatment using them. The norpsilocin compounds include crystalline 4-hydroxy-N-methyltryptamine (“crystalline 4-HO-NMT” or “crystalline norpsilocin freebase”), crystalline 4-hydroxy-N-methyltryptammonium fumarate (“crystalline norpsilocin fumarate”), and 4-hydroxy-N-methyltryptammonium fumarate (“norpsilocin fumarate”) and their compositions and uses.
1. A composition comprising crystalline 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate) and an excipient,
wherein crystalline norpsilocin fumarate is characterized by:
a triclinic, P 1 crystal system space group at a temperature of about 297 K;
unit cell dimensions a=7.7363 (10) Å, b=9.7146 (12) Å, c=9.7854 (13) Å, α=105.524 (4)°, β=110.554 (4)°, and γ=97.167 (4)°;
an XRPD having peaks at 11.5, 13.9, and 16.2°2θ±0.2° 2θ; or
an XRPD pattern substantially similar to FIG. 7 .
2. A composition comprising crystalline 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate) and a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids and (d) a purified terpene,
wherein crystalline norpsilocin fumarate is characterized by:
a triclinic, P 1 crystal system space group at a temperature of about 297 K;
unit cell dimensions a=7.7363 (10) Å, b=9.7146 (12) Å, c=9.7854 (13) Å, α=105.524 (4)°, β=110.554 (4)°, and γ=97.167 (4)°;
an XRPD having peaks at 11.5, 13.9, and 16.2°2θ±0.2° 2θ; or
an XRPD pattern substantially similar to FIG. 7 .
3. 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate).
4. A composition comprising 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate) according to claim 3 and an excipient.
5. A composition comprising 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate) according to claim 3 and a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids and (d) a purified terpene.
6. A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate) according to claim 3 .
7. A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 4 .
8. A method of treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate) according to claim 3 .
9. A method of treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a composition according to claim 4 .
10. A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 5 .
11. A method of treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a composition according to claim 5 .